Abstract
BACKGROUND Warfarin is the most commonly used oral anticoagulant for the treatment and prevention of thromboembolic disorders. Pharmacogenomics studies have shown that variants in CYP2C9 and VKORC1 genes are strongly and consistently associated with warfarin dose variability. METHODOLOGY In this review, we included patients on stable warfarin dose and had the genetics and non-genetics factors associated with mean warfarin dose. We searched PubMed, Medline, Scopus, Google scholar and reference lists of relevant reviews. CONCLUSION Genetic and non-genetic factors affects the dose of warfarin. Genetic factors and Non genetic factors plays a signicant role and that may affects the dose of warfarin
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
